sorafenib - Generic mfg.
Piqray (alpelisib) - Novartis
Rinvoq (upadacitinib) - AbbVie
sulindac - Generic mfg.
Single-Cell RNA Sequencing Reveals Immune Dysregulation and Candidate Drug Targets in Endometriosis. (PubMed, Cells) - Sep 25, 2026 - "Computational drug repurposing analysis prioritized upadacitinib, sorafenib, alpelisib, and sulindac as hypothetical candidates for further investigation, with molecular docking identifying favorable predicted binding affinity scores, particularly for HSP90AA1. These results reinforce a systemic, immune-mediated view of endometriosis and nominate HSP90AA1 and PLCG2 as novel candidate targets that now require biochemical, chemical, and in vivo validation." 
Journal • Endometriosis • Gynecology • Infertility • Inflammation • Pain • Sexual Disorders • Women's Health • CDC37 • HSP90AA1 • PLCG2
http://www.ncbi.nlm.nih.gov/pubmed/42782802
 
Angelika Lackner; Ayberk Alp Gyunesh; Barbara Arbeithuber; Celine Kapper; David Demmel; Diana Reisinger; Esma Hamzic-Jahic; Kévin Lang; Marlene Rezk-Füreder; Matin Kazemi; Peter Oppelt; Sharon D Bryant
 
Sep 25, 2026
 
Prev Next